The study assessed the clinical response to add-on brivaracetam (BRV) in real-world practice by means of time-to-baseline seizure count methodology. Patients with focal epilepsy who were prescribed add-on BRV were identified. Primary endpoint was the time-to-baseline seizure count defined as the number of days until each patient experienced the number of focal seizures that occurred in the 90 days before BRV initiation. Subgroup analysis was performed according to levetiracetam (LEV) status (naive vs prior use). Three-hundred eighty-seven patients were included. The overall median time-to-baseline seizure count was 150 (95% confidence interval [CI] = 130-175) days. The median time-to-baseline seizure count was 198 (lower limit of 95% CI = 168) days for LEV-naive patients, 126 (95% CI = 105-150) days for patients with prior LEV use and withdrawal due to insufficient efficacy, and 170 (95% CI = 128-291) days for patients who discontinued LEV due to adverse events (P =.002). The number of prior antiseizure medications (adjusted hazard ratio [adjHR] = 1.07, 95% CI = 1.02-1.13, P =.009) and baseline monthly seizure frequency (adjHR = 1.004, 95% CI = 1.001-1.008, P =.028) were independently associated with the primary endpoint. Add-on BRV improved seizure control in LEV-naive and LEV-prior patients. The time-to-baseline seizure count represents an informative endpoint alongside traditional study outcomes and designs.

Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis / Lattanzi, S.; De Maria, G.; Rosati, E.; Didato, G.; Chiesa, V.; Ranzato, F.; Canafoglia, L.; Cesnik, E.; Anzellotti, F.; Meletti, S.; Pauletto, G.; Nilo, A.; Bartolini, E.; Marino, D.; Tartara, E.; Luisi, C.; Bonanni, P.; Marrelli, A.; Stokelj, D.; Dainese, F.; Foschi, N.; Cagnetti, C.; Gazzina, S.; Contento, M.; Biggi, M.; Magliani, M.; Di Giacomo, R.; Pastori, C.; Canevini, M. P.; Zambrelli, E.; Billo, G.; Casazza, M.; Fallica, E.; Rosa, G.; Dono, F.; Speranza, R.; Cioclu, C.; Vaudano, A. E.; Kiferle, L.; Galli, R.; Guadagni, M.; Galimberti, C. A.; Kassabian, B.; Ferreri, F.; Osanni, E.; Ciuffini, R.; Badioni, V.; Beretta, S.. - In: EPILEPSIA. - ISSN 0013-9580. - 62:1(2021), pp. e1-e6. [10.1111/epi.16769]

Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis

Ranzato F.;Meletti S.;Marino D.;Rosa G.;Cioclu C.;Vaudano A. E.;Galli R.;
2021

Abstract

The study assessed the clinical response to add-on brivaracetam (BRV) in real-world practice by means of time-to-baseline seizure count methodology. Patients with focal epilepsy who were prescribed add-on BRV were identified. Primary endpoint was the time-to-baseline seizure count defined as the number of days until each patient experienced the number of focal seizures that occurred in the 90 days before BRV initiation. Subgroup analysis was performed according to levetiracetam (LEV) status (naive vs prior use). Three-hundred eighty-seven patients were included. The overall median time-to-baseline seizure count was 150 (95% confidence interval [CI] = 130-175) days. The median time-to-baseline seizure count was 198 (lower limit of 95% CI = 168) days for LEV-naive patients, 126 (95% CI = 105-150) days for patients with prior LEV use and withdrawal due to insufficient efficacy, and 170 (95% CI = 128-291) days for patients who discontinued LEV due to adverse events (P =.002). The number of prior antiseizure medications (adjusted hazard ratio [adjHR] = 1.07, 95% CI = 1.02-1.13, P =.009) and baseline monthly seizure frequency (adjHR = 1.004, 95% CI = 1.001-1.008, P =.028) were independently associated with the primary endpoint. Add-on BRV improved seizure control in LEV-naive and LEV-prior patients. The time-to-baseline seizure count represents an informative endpoint alongside traditional study outcomes and designs.
12-dic-2020
62
1
e1
e6
Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis / Lattanzi, S.; De Maria, G.; Rosati, E.; Didato, G.; Chiesa, V.; Ranzato, F.; Canafoglia, L.; Cesnik, E.; Anzellotti, F.; Meletti, S.; Pauletto, G.; Nilo, A.; Bartolini, E.; Marino, D.; Tartara, E.; Luisi, C.; Bonanni, P.; Marrelli, A.; Stokelj, D.; Dainese, F.; Foschi, N.; Cagnetti, C.; Gazzina, S.; Contento, M.; Biggi, M.; Magliani, M.; Di Giacomo, R.; Pastori, C.; Canevini, M. P.; Zambrelli, E.; Billo, G.; Casazza, M.; Fallica, E.; Rosa, G.; Dono, F.; Speranza, R.; Cioclu, C.; Vaudano, A. E.; Kiferle, L.; Galli, R.; Guadagni, M.; Galimberti, C. A.; Kassabian, B.; Ferreri, F.; Osanni, E.; Ciuffini, R.; Badioni, V.; Beretta, S.. - In: EPILEPSIA. - ISSN 0013-9580. - 62:1(2021), pp. e1-e6. [10.1111/epi.16769]
Lattanzi, S.; De Maria, G.; Rosati, E.; Didato, G.; Chiesa, V.; Ranzato, F.; Canafoglia, L.; Cesnik, E.; Anzellotti, F.; Meletti, S.; Pauletto, G.; Nilo, A.; Bartolini, E.; Marino, D.; Tartara, E.; Luisi, C.; Bonanni, P.; Marrelli, A.; Stokelj, D.; Dainese, F.; Foschi, N.; Cagnetti, C.; Gazzina, S.; Contento, M.; Biggi, M.; Magliani, M.; Di Giacomo, R.; Pastori, C.; Canevini, M. P.; Zambrelli, E.; Billo, G.; Casazza, M.; Fallica, E.; Rosa, G.; Dono, F.; Speranza, R.; Cioclu, C.; Vaudano, A. E.; Kiferle, L.; Galli, R.; Guadagni, M.; Galimberti, C. A.; Kassabian, B.; Ferreri, F.; Osanni, E.; Ciuffini, R.; Badioni, V.; Beretta, S.
File in questo prodotto:
File Dimensione Formato  
Brivaracetam as add-on treatment in focal epilepsy_A real-world 10.1111@epi.16769.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 373.12 kB
Formato Adobe PDF
373.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1226000
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
social impact